Background For ampullary carcinoma (AC), the lymph node ratio (LNR) has been associated with overall survival. However, the use of the LNR to predict distant recurrence risk remains unknown. The purpose of this study was to determine if the LNR is associated with distant recurrence risk. Methods One hundred forty three patients with AC who underwent pancreaticoduodenectomy between 1989 and 2011 were identified from a single-institution prospective database. Data on clinicopathologic factors and recurrence were analyzed. Results At a median follow-up of 43 months (62 months for survivors), 55 patients (38 %) had developed recurrent disease, with a median time to recurrence of 13 months. Patients with a LNR ≥0.15 were more likely to have T3/4 tumors, advanced stage lymphovascular (LVI), or perineural invasion (PNI) and develop recurrent disease. Univariate analysis demonstrated that T-stage, lymph node status, AJCC stage, LVI, PNI, and LNR were significantly associated with decreased time to distant recurrence (TTDR). In multivariate stepwise regression, only LNR and LVI were significantly associated with decreased TTDR. Conclusions A high positive LNR is associated with distant recurrence after surgical resection of AC. Given the high risk of disease recurrence, consideration for adjuvant therapy is warranted in patients with a LNR ≥0.15.
Introduction
Although patients with ampullary carcinoma (AC) have improved survival compared to patients with pancreatic adenocarcinoma, up to 40 % of patients develop recurrent disease, highlighting the importance of adjuvant therapy. 1 Several factors have been associated with outcomes for patients with AC, including advanced T-stage, tumor grade, pancreatobiliary histologic subtype, tumor budding, lymphovascular (LVI) or perineural invasion (PNI), and nodepositive disease. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Recently, the lymph node ratio (LNR), defined as the number of nodes with metastatic disease among the total number of retrieved nodes, has demonstrated prognostic utility for overall survival in many types of malignancies including pancreatic, colon, breast, gastric, and esophageal carcinoma. [19] [20] [21] [22] [23] [24] [25] For AC, using the LNR as a categorical variable, previous studies have shown a cutoff point between 0.1 and 0.2 as having prognostic significance for overall survival. 7, 11, 26 However, the use of the LNR to predict distant recurrence risk remains unknown. The current study was conducted to identify factors associated with distant recurrence for patients with surgically resected AC with specific focus on pathologic data available to the health care team after pancreaticoduodenectomy (PD).
Methods
This retrospective study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center. We retrieved clinical data on all patients who underwent PD for AC between 1989 and 2011 from our prospectively maintained, institutional AC database. 27 We excluded from analysis patients with a final diagnosis of invasive adenocarcinoma arising from the pancreas or duodenum.
Treatment Sequencing and Therapy
Our multidisciplinary team coordinated the treatment algorithm for each patient. PD was performed using standardized technique. 28 Specifically, in every case, the SMV was completely mobilized to expose the proximal SMA. Dissection of the uncinate process from the retroperitoneum was then performed directly along the periadventitial plane of the SMA to remove all the soft tissue to the right of the SMA and thereby maximize the SMA margin distance. 28, 29 Recommendations to offer preoperative chemoradiation was driven by the clinician's assessment of risk of regional disease including such factors as T-stage, poorly differentiated tumors, or the presence of lymphovascular or perineural invasion on biopsy. In addition, patients with marginal performance status or who possess a moderate to high surgical risk were also offered preoperative chemoradiation to facilitate additional cardiovascular work-up and improvement of nutritional parameters. For those patients who underwent preoperative chemoradiation, diagnosis was established with endoscopic ultrasound and biopsy. Significant complications were defined as those requiring inpatient hospitalization. The decision to administer postoperative therapy was influenced by the prevalence of high-risk factors, the perceived benefit of adjuvant therapy, the bias of the surgeon, and the referral pattern. Biliary decompression was accomplished with a plastic or metal stent before preoperative chemoradiation. 30 Patients were staged according to the American Joint Committee on Cancer (AJCC) staging guidelines. 31 Follow-up and Definitions of Recurrence After surgery, patients were evaluated every 4 months with a physical examination, chest radiography, and abdominal CT. For patients with no evidence of disease after 2 years of follow-up, evaluations were reduced to 6-month intervals. The development of a new low-density mass or abdominal lymphadenopathy in the region of the resected pancreas or mesenteric root was considered locoregional recurrence in this area. Radiographic evidence of a low-density mass in the liver or lungs or new-onset ascites was considered evidence for distant recurrence. Biopsy of recurrence was rarely performed. Only the first site(s) of recurrent disease was documented for this study. Time to distant recurrence (TTDR) is defined as from the time of surgery to the time of first distant recurrence or to the time of last contact.
Statistics
For categorical variables, descriptive statistics were compared using χ 2 or Fisher's exact test; Wilcoxon's rank sum test (t test) and the Kruskal-Wallis test (ANOVA) were used to compare the distributions of continuous variable among different groups. TTDR was defined as the interval between the date of resection and first evidence of distant recurrence or last follow-up if recurrence was not observed. The Kaplan-Meier product limit method was used to estimate the median survival time and median time to distant recurrence. The Cox proportional hazards regression model, in which a backward elimination process was used for variable selection with an entry and removal limit of p<0.1 and p<0.05, respectively, was applied to identify independent factors associated with TTDR. Statistical analysis was performed using STATA/SE version 12.0 statistical software (Stata Corp. LP, College Station, TX).
Results

Clinicopathologic Characteristics Associated with Distant Recurrence
The clinicopathologic and treatment characteristics of 143 consecutive patients with histologically confirmed AC who underwent PD between 1989 and 2011 are reported in Table 1 . Median overall survival was 101 months with a median clinical follow-up time of 43 months (range, 1-222), 62 months for survivors. Thirty-three patients (23 %) received preoperative chemoradiation. Median tumor size was 1.8 cm and 98 % of patients underwent a margin-negative resection. Among the 143 patients, 72 (50 %) had N1 disease. Twenty-five patients (17 %) developed a perioperative complication with one perioperative mortality.
Fifty-five patients (38 %) developed recurrent disease, with a median time to recurrence of 13 months ( Fig. 1 and Table 1 ). These two groups were compared, and several factors were identified as significantly different between patients that developed a recurrence and those who did not. Patients with recurrent disease were more likely to have advanced T-stage (p00.007), lymph node-positive (N1) disease (p00.001), higher LNR (p<0.001), advanced AJCC stage (p00.002), LVI (p00.003), or PNI (p00.002). There was no difference in the number of lymph nodes harvested between the groups. The median number of lymph nodes involved was 1 (0-14) with a LNR of 0.02 (range, 0-0.82; Table 1 ). The median LNR for N1 patients was 0.13 (range, 0.01-0.82). 33 (23) 15 (27) 18 (20) 0.437 Post-op chemotherapy, n (%)
28 (20) 13 (24) 15 (17) 0.251 Post-op chemoradiation, n (%)
34 (24) 14 (25) 20 (23) Given the identification of LNR as a factor highly associated with distant recurrence, we sought to understand the relative impact of subgroups based upon LNR. LNR was stratified into the following groups: 0, 0.1-0.14, and ≥0.15 (Table 2) . These cutoff points were chosen for two reasons: (1) they included the range of LNRs found to have a significant relation with survival in previous studies, 7, 11, 26 and (2) they were centered around the median LNR for N1 patients in our dataset. Although there was no difference in the rate of preoperative chemoradiation between the groups, patients with N1 disease (LNR ≥0.01) were more like to receive postoperative chemotherapy and/or chemoradiation. Patients with a high LNR (≥0.15) were more likely to have T3/4 tumors, advanced AJCC stage, LVI, or PNI. At last follow-up, 22 patients (73 %) with a high LNR developed recurrent disease, of which the majority had a component of distant failure (Table 2) . Sixteen patients developed a local recurrence, and there was no difference in the local recurrence rate based on LNR. Eight patients developed simultaneous local and distant recurrences. The pattern of recurrence is listed in Table 2 .
The univariate analysis shown in Table 3 demonstrates that T-stage (p00.014), lymph node status (p0 0.001), AJCC stage (p00.012), LVI (p00.005), PNI (p0 0.02), and LNR ≥0.15 (p<0.001, Fig. 1 ) were significantly associated with decreased TTDR. Patients with a LNR ≥0.15 had the shortest time to distant recurrence with a median of 13 months (Table 3 and Fig. 1b) . Interestingly, patients with N0 disease and a low LNR (LNR00.01-0.14) had similar 3-year distant recurrence rates (21.2 vs. 24.6 %; p00.499; Table 3 ). All further examined parameters including the number of examined lymph nodes, tumor size, CA 19-9 level, preoperative chemoradiation, and degree of differentiation did not influence TTDR (data not shown). In the multivariate Cox stepwise regression model, only LNR ≥0.15 and LVI were significantly associated with decreased TTDR (Table 4) .
Discussion
Patients with AC have improved outcomes compared to patients with pancreatic adenocarcinoma. However, local and distant failure remains a long-term problem.
2,32-34
Metastatic disease to regional lymph nodes has consistently represented a strong predictor of survival and recurrence risk. 1, 9, 12, [16] [17] [18] Our study is the first to report the use of the LNR as a predictor of distant recurrence risk in patients who underwent resection for AC. Similar to previous studies, 38 % of patients in this study developed recurrent disease, with the majority having some component of distant failure (Table 2) . 1, 9 In this study, patients with a LNR ≥0.15 had significantly decreased TTDR than patients with nodenegative or low LNR (LNR 00.01-0.14; Table 4 and Fig. 1b) . Patients with a high LNR were more likely to have advanced T-stage, LVI, and PNI. The theoretical benefit of the LNR is the standardization of lymph node positivity, while controlling for the number of lymph nodes retrieved. This is most effectively demonstrated for patients with a LNR ≥0.15. Forty percent of patients in the high LNR had one to three positive lymph nodes, 33 % had four to six positive lymph nodes, and 27 % had seven or more positive lymph nodes (Table 2 ). If these patients had been staged based on the number of positive lymph nodes, in our opinion, 40 % of these patients would have been inappropriately under-staged. Ninety-eight percent of patients had a microscopically negative resection, highlighting the importance of tumor biology on recurrence risk. Interestingly, we found no difference in the risk of distant recurrence between patients with node-negative disease or a low LNR. Patients with a low LNR were more likely than patients with node-negative disease to receive postoperative chemotherapy or chemoradiation, which could account for this finding.
Several studies have evaluated factors associated with the development of recurrent disease. 2, 4, 5, [8] [9] [10] [11] 15, 26, 35 Advanced T-stage, LVI, and PNI have repeatedly been shown to be important predictors of recurrence risk. The use of ancillary pathologic tests, such as tumor budding, loss of β-catenin and osteopontin staining has demonstrated prognostic value Fig. 1 Kaplan-Meier estimate of time to distant recurrence for ampullary carcinoma patients after pancreaticoduodenectomy for a an entire cohort and b by LNR for recurrence risk. 10, 13, 14 However, these tests require additional evaluation outside of routine TNM staging, making them more expensive and labor-intensive. In this study, multivariate analysis demonstrated the lymph node ratio and the presence of lymphovascular invasion as the only clinicopathologic factors associated with an increased risk of distant recurrence ( Fig. 1 and Table 4 ). Twenty-five percent of patients in this study received preoperative chemoradiation. The utility of the LNR for patients that have undergone preoperative therapy has not been validated. However, in this study, patients that received preoperative therapy had equivalent survival and LNR distribution as those that did not have preoperative therapy (data not shown). Interestingly, patients that received preoperative therapy were less likely to have LVI on final pathologic analysis compared to patients that had postoperative therapy or surgery alone (25 vs. 56 vs. 52 %, respectively; p<0.001). Thus, the data suggest that the delivery of preoperative therapy may reduce LVI in patients with AC. As the sample size for the preoperative therapy group is small (33 patients), it is difficult to draw any firm conclusions regarding this data, but it presents an interesting finding that warrants further investigation. The current study has several limitations: the retrospective nature of the analysis, the small number of patients treated over a long time period, and the variability in the use of preoperative and postoperative adjuvant therapy. We believe, however, that these limitations did not greatly affect the results of the study as the differences between the groups were too marked to have resulted from bias.
At present, adjuvant therapy is not considered standard therapy for ampullary carcinoma. The decision to administer adjuvant therapy is driven by the clinician's assessment of risk of disease recurrence. Currently, lymph node status is one of the strongest factors associated with treatment failure. In the current study, 38 % of patients developed recurrent disease, of which the majority had some component of distant failure. However, patients with a LNR ≥0.15 had a 3-year distant recurrence rate of 61 % which identifies them as a high-risk subset. Interestingly, 37 % of these patients did not receive postoperative therapy. The benefit of adjuvant chemotherapy and chemoradiation has been demonstrated in several recent studies. The largest randomized trial evaluating the benefit of adjuvant chemotherapy for patients with ampullary carcinoma was recently completed. The ESPAC-3 trial was a large, phase 3 trial from 100 centers in Europe, Australia, Japan, and Canada that randomized patients with periampullary adenocarcinomas to observation vs. folinic acid and fluorouracil or gemcitabine. After adjusting for age, bile duct cancer, poor tumor differentiation, and positive lymph nodes, the hazard ratio for patients receiving chemotherapy was 0.75 (p00.03). 36 A large cooperative analysis from Johns Hopkins and the Mayo Clinic demonstrated a significant survival benefit for patients who received adjuvant chemoradiation.
1 A recent retrospective study of 137 patients demonstrated that a 3-year local control was improved in patients receiving chemoradiation therapy (88 vs. 55 %, p00.001). These multi- institutional data support the use of adjuvant therapy in patients with high-risk ampullary carcinoma, and this study identifies LNR ≥0.15 as a marker for patients who could benefit from systemic therapy after surgical resection.
Conclusion
A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. Given the high risk of disease recurrence, consideration for adjuvant therapy is should be considered in patients with a LNR ≥0.15.
